newsfilter
← Latest News
PR Newswire·

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Positive changes in ALS gene expression and increased cellular viability met with statistical significance of p<.001 NEW YORK, Sept. 7, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or